PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Clin Cancer Res. 2016 Sep 15;22(18):4539-41. doi: 10.1158/1078-0432.CCR-16-1401. Epub 2016 Jul 28.

Abstract

Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immunotherapeutics for advanced smoking-associated non-small cell lung cancer. Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. Clin Cancer Res; 22(18); 4539-41. ©2016 AACRSee related article by Gainor et al., p. 4585.

Publication types

  • Letter

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • ErbB Receptors / genetics*
  • ErbB Receptors / metabolism
  • Gene Rearrangement
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / etiology*
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Molecular Targeted Therapy
  • Mutation
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Tumor Microenvironment / drug effects
  • Tumor Microenvironment / genetics
  • Tumor Microenvironment / immunology

Substances

  • Antineoplastic Agents
  • Programmed Cell Death 1 Receptor
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • EGFR protein, human
  • ErbB Receptors
  • Receptor Protein-Tyrosine Kinases